Supplementary drug treatment to reduce weight in adolescents with severe obesity

Johannes Rolin; Rønnaug Astri Ødegård; Viktoria Vedeler Amundsen; Unni Mette Stamnes Köpp; Ane Kokkvoll; Pétur Benedikt Júlíusson; Jøran Hjelmesæth

doi:10.4045/tidsskr.22.0540

Supplementary drug treatment to reduce weight in adolescents with severe obesity

Tidsskr Nor Laegeforen. 2022 Oct 4;142(14). doi: 10.4045/tidsskr.22.0540. Print 2022 Oct 11.

[Article in English, Norwegian]

Authors

Johannes Rolin, Rønnaug Astri Ødegård, Viktoria Vedeler Amundsen, Unni Mette Stamnes Köpp, Ane Kokkvoll, Pétur Benedikt Júlíusson, Jøran Hjelmesæth¹

Affiliation

¹ Senter for sykelig overvekt I Helse Sør-Øst.

PMID: 36226431
DOI: 10.4045/tidsskr.22.0540

No abstract available

Plain language summary

In 2021, the Norwegian Medicines Agency approved the use of daily injection of liraglutide 3.0 mg (Saxenda) as a supplement to lifestyle treatment for weight control in children ≥ 12 years of age with obesity (isoBMI ≥ 30). We share the treatment experiences of six multidisciplinary obesity clinics in the specialist health service.

MeSH terms

Adolescent
Anti-Obesity Agents* / therapeutic use
Humans
Obesity / drug therapy
Obesity, Morbid* / drug therapy

Substances

Anti-Obesity Agents